Meta-analysis comparing dual antiplatelet therapy vs single antiplatelet therapy following transcatheter aortic valve implantation
American Journal of Cardiology Jul 25, 2018
Siddamsetti S, et al. - Researchers analyzed data from all the trials comparing dual antiplatelet therapy (DAPT) to single antiplatelet therapy (SAPT) in patients undergoing transcathter aortic valve implantation (TAVI) via a meta-analysis including three randomized trials and four non-randomized studies. The rate of ischemic stroke was the primary endpoint, and the rates of myocardial infarction (MI), life threatening bleeding (LTB), significant bleeding (LTB and major bleeding), and death being the secondary end points. They used Mantel-Haenszel random effects model to calculate the combined odds ratios (OR) and 95% confidence intervals (CI) for outcomes at 30 days and up to 6-12 months follow-up. Based on the findings, they concluded no additional benefit of DAPT over SAPT following TAVI, as no difference in mortality, ischemic stroke and MI at 30 days or 6-12 month follow up was seen.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries